Glaucoma

Top Story

Roclatan meets primary efficacy endpoint in phase 3 study

May 25, 2017

Roclatan, a once-daily fixed-dose combination drug for lowering IOP, has achieved its primary efficacy endpoint in the Mercury 2 phase 3 study, Aerie Pharmaceuticals announced in a press release.

The 90-day trial compared Roclatan — a combination of Rhopressa (netarsudil ophthalmic solution 0.02%) and latanoprost — with monotherapy of each of its components. IOP was measured three times daily at 2 weeks, 6 weeks and 90 days. Roclatan reduced IOP between 1.5 mm Hg and 2.4 mm Hg more than latanoprost alone and between 2.2 mm Hg and 3.3 mm Hg more than Rhopressa alone, the release said.

Two iStent procedure may be more cost-efficient than other IOP-lowering treatments

May 23, 2017
In treating elevated IOP in open-angle glaucoma patients, two iStent trabecular micro-bypass stents had a lower projected cumulative cost after 5 years compared with…
Meeting NewsVideo

VIDEO: In-office electrophysiology helps detect, monitor glaucoma damage

May 23, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery meeting here, Brian A. Francis, MD, MS, discusses how in-office electrophysiology using pattern…
Meeting NewsVideo

VIDEO: Pulsed laser glaucoma treatment reduces IOP, medications

May 22, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery meeting here, Rolando Toyos, MD, discusses his work with pulsed laser in the treatment of…
Clinical Science

Long-Term Experience of Patch Graft Failure After Ahmed Glaucoma Valve® Surgery Using Donor Dura and Sclera Allografts

Ophthalmic Surgery, Lasers and Imaging Retina, September 2012, Volume 43 Issue 5
To report the long-term incidence, timing, and experience of patch graft failure (PGF) after Ahmed Glaucoma Valve (AGV)…
More »
CME

Glaucoma: Novel Mechanisms and Treatments that Target the Elusive IOP

This activity is supported by an educational grant from Bausch + Lomb.

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to…
More »
Featured
Video
Meeting News

VIDEO: Cyclophotocoagulation with micropulse technology reveiw

January 26, 2017
More »

Roclatan meets primary efficacy endpoint in phase 3 study

May 25, 2017
Roclatan, a once-daily fixed-dose combination drug for lowering IOP, has achieved its primary efficacy endpoint in the

Two iStent procedure may be more cost-efficient than other IOP-lowering treatments

May 23, 2017
In treating elevated IOP in open-angle glaucoma patients, two iStent trabecular micro-bypass stents had a lower projected cumulative cost after 5…

Meeting NewsVideo

VIDEO: In-office electrophysiology helps detect, monitor glaucoma damage

May 23, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery meeting here, Brian A. Francis, MD, MS, discusses how in-office…

Meeting NewsVideo

VIDEO: Pulsed laser glaucoma treatment reduces IOP, medications

May 22, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery meeting here, Rolando Toyos, MD, discusses his work with pulsed laser in…

Meeting NewsVideo

VIDEO: LensGen founder discusses impact of funding on IOL development

May 17, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery here, Ramgopal Rao, LensGen’s CEO and founder, discusses the…

Meeting NewsVideo

VIDEO: Real-world Xen glaucoma implant technique improves on FDA-approved technique

May 16, 2017
BALTIMORE ― At the Association for Research in Vision and Ophthalmology meeting here, Davinder S. Grover, MD, MPH, discusses an FDA-approved…

Blog

BLOG: Get under your shelter, the glaucoma storm is upon us

May 16, 2017
If you haven’t remained current with what is going on in the field of glaucoma, then you might have woken up in the eye of the hurricane. It…

Meeting News

Study examines growth trends of anterior segment anatomy

May 15, 2017
BALTIMORE — Anterior segment anatomy and structural changes with eye growth show logarithmic growth trends, with maximal growth rates in the…

Meeting News

Micropulse transscleral cyclophotocoagulation reduces IOP in advanced primary open angle glaucoma

May 12, 2017
LOS ANGELES — Micropulse transscleral diode laser cyclophotocoagulation is a safe and promising IOP-lowering treatment for patients with…

Grand Rounds at the New England Eye Center

Man presents with red eye and ocular hypertension

Ocular Surgery News U.S. Edition, May 25, 2017
Astrid Werner, MD; Alan Barlow, MD
A 55-year-old male construction worker with no ocular history presented to the Tufts New England Eye Center Comprehensive Ophthalmology Clinic for…

More Headlines »
Advertisement
Advertisement